AF
CTMX icon

Amalgamated Financial’s CytomX Therapeutics CTMX Stock Holding History

Amalgamated Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$27K Buy
+10,184
New +$39.1K ﹤0.01% 2650

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Amalgamated Financial's CTMX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in CytomX Therapeutics (CTMX) in Q1 2022: 10,184 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #2650 among its holdings.

119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

  • Amalgamated Financial held 10,184 shares of CytomX Therapeutics worth $27K as of Q1 2022.
  • CytomX Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • CytomX Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2650 holding.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.